We report a chemoselective and site-selective approach that distinguishes one Lys from its multiple copies, N-terminus, and other competitors. The phospha-Mannich protocol works with multiple proteins and installs probes without structural and functional perturbations. It delivers an antibody-drug conjugate with selective anti-proliferative activity towards HER2 expressing SKBR3 breast cancer cells.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1039/c8cc03311k | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!